MedTrace Logo

Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

NCT00108706 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-09-13

No results posted yet for this study

Summary

The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.

Conditions

  • Cerebrovascular Accident
  • Acute Stroke

Interventions

DRUG

Candesartan

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • City Hospitals Sunderland NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Christopher S Gray, MD · University of Newcastle Upon-Tyne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2007-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00108706 on ClinicalTrials.gov